Trial Profile
Temozolomide plus bevacizumab for newly-diagnosed glioblastoma in the elderly over 75
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 12 May 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 05 Aug 2014 New trial record